Management of Severe Hematochezia in Patients with C. difficile and AML with Febrile Neutropenia

Initial Assessment and Management

The World Journal of Emergency Surgery recommends oral vancomycin 125-500 mg four times daily for C. difficile infection combined with broad-spectrum antibiotics for febrile neutropenia, with consideration of higher initial vancomycin doses (250-500 mg QID) for the first 24-48 hours in severe cases 1
Oral vancomycin 125 mg four times daily for 10 days is considered superior to metronidazole for severe C. difficile infection 1
Higher doses of vancomycin (up to 500 mg QID) may be used in patients with severe or fulminant C. difficile infection, although evidence supporting this practice is limited 1
Fidaxomicin 200 mg twice daily for 10 days may be a valid alternative, particularly in patients at high risk for recurrence 1
If possible, discontinue antibiotics being used for infections other than C. difficile, as continued use significantly increases risk of CDI recurrence 1
If continued antibiotic therapy is required, use agents less frequently implicated with antibiotic-associated CDI (parenteral aminoglycosides, sulfonamides, macrolides, vancomycin, or tetracycline/tigecycline) 1
Initiate broad-spectrum β-lactam with antipseudomonal activity immediately 2

Obtain blood cultures from peripheral vein and all indwelling catheters before starting antibiotics 3
Assess for hemodynamic stability and provide vigorous resuscitation if necessary 3
Patients with lung infiltrates not typical for Pneumocystis pneumonia or lobar bacterial pneumonia should receive mold-active systemic antifungal therapy with voriconazole or liposomal amphotericin B 2
Consider antifungal therapy when fever persists for >4-6 days despite antibacterial therapy 4

Perform daily assessment of fever trends, bone marrow and renal function until the patient is afebrile and absolute neutrophil count ≥0.5×10⁹/L 4
Reassess response to therapy at 48 hours 4
If still febrile at 48 hours:
- If clinically stable: continue initial antibacterial therapy 4
- If clinically unstable: broaden antibacterial coverage and seek infectious disease consultation 4

For fulminant C. difficile infection with systemic toxicity, early surgical consultation should be obtained 1
Fecal microbiota transplantation (FMT) may be considered for refractory cases, even in neutropenic patients, though this carries risks and should be reserved for life-threatening cases 1
Bezlotoxumab (monoclonal antibody against C. difficile toxin B) may prevent recurrences of CDI, particularly in immunocompromised patients and those with severe CDI 1

When using antifungals such as posaconazole or voriconazole with certain AML therapies (midostaurin, glasdegib, venetoclax), monitor for QT interval prolongation and consider dose adjustments 5
Venetoclax dose should be reduced by 75% when administered with posaconazole 7

Do not delay antibiotic therapy - start within 1 hour of presentation 3
Do not use alcohol-based hand sanitizers when caring for patients with C. difficile, as they may not kill C. difficile spores; handwashing with soap and water is most effective 1
Avoid unnecessary broad-spectrum antibiotics in patients who have recovered from neutropenia and are afebrile 3
Do not overlook non-bacterial causes of persistent fever, including fungal infections, viral infections, and drug fever 3